nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MET—bile duct cancer	0.7	1	CbGaD
Crizotinib—PRKD3—pancreas—bile duct cancer	0.00177	0.0181	CbGeAlD
Crizotinib—MAPK7—pancreas—bile duct cancer	0.00164	0.0167	CbGeAlD
Crizotinib—MET—pancreas—bile duct cancer	0.00153	0.0157	CbGeAlD
Crizotinib—ACVR1B—pancreas—bile duct cancer	0.00142	0.0145	CbGeAlD
Crizotinib—IKBKE—lymph node—bile duct cancer	0.00138	0.0141	CbGeAlD
Crizotinib—NEK9—liver—bile duct cancer	0.00129	0.0132	CbGeAlD
Crizotinib—IGF1R—pancreas—bile duct cancer	0.0012	0.0123	CbGeAlD
Crizotinib—SIK2—liver—bile duct cancer	0.00116	0.0118	CbGeAlD
Crizotinib—PRKD3—liver—bile duct cancer	0.00113	0.0115	CbGeAlD
Crizotinib—CASK—liver—bile duct cancer	0.00108	0.011	CbGeAlD
Crizotinib—NUAK2—pancreas—bile duct cancer	0.00107	0.011	CbGeAlD
Crizotinib—ACVR1—pancreas—bile duct cancer	0.00107	0.0109	CbGeAlD
Crizotinib—STK35—pancreas—bile duct cancer	0.00104	0.0107	CbGeAlD
Crizotinib—FES—liver—bile duct cancer	0.00103	0.0105	CbGeAlD
Crizotinib—NEK9—lymph node—bile duct cancer	0.000987	0.0101	CbGeAlD
Crizotinib—MET—liver—bile duct cancer	0.000975	0.00997	CbGeAlD
Crizotinib—CDK7—liver—bile duct cancer	0.000943	0.00965	CbGeAlD
Crizotinib—TAOK2—liver—bile duct cancer	0.000936	0.00957	CbGeAlD
Crizotinib—ACVR1B—liver—bile duct cancer	0.000902	0.00922	CbGeAlD
Crizotinib—PRKD1—lymph node—bile duct cancer	0.000899	0.0092	CbGeAlD
Crizotinib—PTK2—pancreas—bile duct cancer	0.000894	0.00914	CbGeAlD
Crizotinib—TBK1—pancreas—bile duct cancer	0.000894	0.00914	CbGeAlD
Crizotinib—TYK2—pancreas—bile duct cancer	0.000888	0.00908	CbGeAlD
Crizotinib—LIMK1—lymph node—bile duct cancer	0.000887	0.00907	CbGeAlD
Crizotinib—IRAK1—pancreas—bile duct cancer	0.000877	0.00896	CbGeAlD
Crizotinib—PRKD3—lymph node—bile duct cancer	0.000865	0.00884	CbGeAlD
Crizotinib—RPS6KB1—pancreas—bile duct cancer	0.00086	0.0088	CbGeAlD
Crizotinib—STK4—liver—bile duct cancer	0.000844	0.00863	CbGeAlD
Crizotinib—DSTYK—lymph node—bile duct cancer	0.000844	0.00863	CbGeAlD
Crizotinib—BLK—lymph node—bile duct cancer	0.000834	0.00853	CbGeAlD
Crizotinib—LTK—lymph node—bile duct cancer	0.000825	0.00843	CbGeAlD
Crizotinib—CASK—lymph node—bile duct cancer	0.000825	0.00843	CbGeAlD
Crizotinib—SLK—pancreas—bile duct cancer	0.00082	0.00838	CbGeAlD
Crizotinib—EPHB4—pancreas—bile duct cancer	0.000814	0.00832	CbGeAlD
Crizotinib—MAPK7—lymph node—bile duct cancer	0.000799	0.00817	CbGeAlD
Crizotinib—TXK—lymph node—bile duct cancer	0.000799	0.00817	CbGeAlD
Crizotinib—EPHA2—pancreas—bile duct cancer	0.000798	0.00816	CbGeAlD
Crizotinib—FER—liver—bile duct cancer	0.000798	0.00816	CbGeAlD
Crizotinib—LYN—liver—bile duct cancer	0.000794	0.00812	CbGeAlD
Crizotinib—FES—lymph node—bile duct cancer	0.000791	0.00809	CbGeAlD
Crizotinib—TNK1—liver—bile duct cancer	0.00079	0.00807	CbGeAlD
Crizotinib—MAP4K5—pancreas—bile duct cancer	0.000779	0.00796	CbGeAlD
Crizotinib—TEK—pancreas—bile duct cancer	0.000779	0.00796	CbGeAlD
Crizotinib—TNK2—liver—bile duct cancer	0.000767	0.00784	CbGeAlD
Crizotinib—IGF1R—liver—bile duct cancer	0.000767	0.00784	CbGeAlD
Crizotinib—MAP4K2—liver—bile duct cancer	0.000756	0.00773	CbGeAlD
Crizotinib—MET—lymph node—bile duct cancer	0.000748	0.00765	CbGeAlD
Crizotinib—STK3—liver—bile duct cancer	0.000746	0.00762	CbGeAlD
Crizotinib—TIE1—liver—bile duct cancer	0.000746	0.00762	CbGeAlD
Crizotinib—AURKA—liver—bile duct cancer	0.000727	0.00743	CbGeAlD
Crizotinib—CDK7—lymph node—bile duct cancer	0.000723	0.0074	CbGeAlD
Crizotinib—TESK1—liver—bile duct cancer	0.000721	0.00737	CbGeAlD
Crizotinib—YES1—pancreas—bile duct cancer	0.000719	0.00735	CbGeAlD
Crizotinib—TAOK2—lymph node—bile duct cancer	0.000718	0.00734	CbGeAlD
Crizotinib—TAOK3—pancreas—bile duct cancer	0.00071	0.00726	CbGeAlD
Crizotinib—MERTK—liver—bile duct cancer	0.000701	0.00717	CbGeAlD
Crizotinib—SRC—pancreas—bile duct cancer	0.000692	0.00708	CbGeAlD
Crizotinib—EPHA3—lymph node—bile duct cancer	0.000691	0.00707	CbGeAlD
Crizotinib—ACVR1B—lymph node—bile duct cancer	0.000691	0.00707	CbGeAlD
Crizotinib—LIMK2—liver—bile duct cancer	0.000686	0.00701	CbGeAlD
Crizotinib—NUAK2—liver—bile duct cancer	0.000683	0.00699	CbGeAlD
Crizotinib—MAP3K12—liver—bile duct cancer	0.000678	0.00694	CbGeAlD
Crizotinib—FLT3—liver—bile duct cancer	0.000678	0.00694	CbGeAlD
Crizotinib—ACVR1—liver—bile duct cancer	0.000678	0.00694	CbGeAlD
Crizotinib—STK35—liver—bile duct cancer	0.000665	0.0068	CbGeAlD
Crizotinib—JAK3—lymph node—bile duct cancer	0.000659	0.00674	CbGeAlD
Crizotinib—DCLK1—lymph node—bile duct cancer	0.000655	0.0067	CbGeAlD
Crizotinib—PLK4—lymph node—bile duct cancer	0.000651	0.00666	CbGeAlD
Crizotinib—ABL2—liver—bile duct cancer	0.000648	0.00662	CbGeAlD
Crizotinib—STK4—lymph node—bile duct cancer	0.000647	0.00662	CbGeAlD
Crizotinib—BMP2K—liver—bile duct cancer	0.00064	0.00654	CbGeAlD
Crizotinib—PTK2B—liver—bile duct cancer	0.000618	0.00632	CbGeAlD
Crizotinib—RIPK2—liver—bile duct cancer	0.000613	0.00627	CbGeAlD
Crizotinib—ALK—lymph node—bile duct cancer	0.000612	0.00625	CbGeAlD
Crizotinib—FER—lymph node—bile duct cancer	0.000612	0.00625	CbGeAlD
Crizotinib—TNK1—lymph node—bile duct cancer	0.000605	0.00619	CbGeAlD
Crizotinib—BMPR1B—lymph node—bile duct cancer	0.000599	0.00613	CbGeAlD
Crizotinib—MAP4K1—lymph node—bile duct cancer	0.000599	0.00613	CbGeAlD
Crizotinib—TNK2—lymph node—bile duct cancer	0.000588	0.00601	CbGeAlD
Crizotinib—IGF1R—lymph node—bile duct cancer	0.000588	0.00601	CbGeAlD
Crizotinib—MAP3K2—liver—bile duct cancer	0.000581	0.00594	CbGeAlD
Crizotinib—MAP4K2—lymph node—bile duct cancer	0.00058	0.00593	CbGeAlD
Crizotinib—TIE1—lymph node—bile duct cancer	0.000572	0.00585	CbGeAlD
Crizotinib—STK3—lymph node—bile duct cancer	0.000572	0.00585	CbGeAlD
Crizotinib—TBK1—liver—bile duct cancer	0.000569	0.00582	CbGeAlD
Crizotinib—PTK2—liver—bile duct cancer	0.000569	0.00582	CbGeAlD
Crizotinib—TYK2—liver—bile duct cancer	0.000565	0.00578	CbGeAlD
Crizotinib—IRAK1—liver—bile duct cancer	0.000558	0.0057	CbGeAlD
Crizotinib—AURKA—lymph node—bile duct cancer	0.000557	0.0057	CbGeAlD
Crizotinib—TESK1—lymph node—bile duct cancer	0.000553	0.00565	CbGeAlD
Crizotinib—RPS6KB1—liver—bile duct cancer	0.000547	0.0056	CbGeAlD
Crizotinib—FGR—liver—bile duct cancer	0.000544	0.00556	CbGeAlD
Crizotinib—LCK—liver—bile duct cancer	0.000544	0.00556	CbGeAlD
Crizotinib—AXL—liver—bile duct cancer	0.000542	0.00554	CbGeAlD
Crizotinib—MERTK—lymph node—bile duct cancer	0.000538	0.0055	CbGeAlD
Crizotinib—LIMK2—lymph node—bile duct cancer	0.000526	0.00538	CbGeAlD
Crizotinib—NUAK2—lymph node—bile duct cancer	0.000524	0.00536	CbGeAlD
Crizotinib—SLK—liver—bile duct cancer	0.000522	0.00533	CbGeAlD
Crizotinib—ACVR1—lymph node—bile duct cancer	0.00052	0.00532	CbGeAlD
Crizotinib—FLT3—lymph node—bile duct cancer	0.00052	0.00532	CbGeAlD
Crizotinib—MAP3K12—lymph node—bile duct cancer	0.00052	0.00532	CbGeAlD
Crizotinib—EPHB4—liver—bile duct cancer	0.000518	0.00529	CbGeAlD
Crizotinib—JAK2—liver—bile duct cancer	0.000514	0.00526	CbGeAlD
Crizotinib—STK35—lymph node—bile duct cancer	0.00051	0.00521	CbGeAlD
Crizotinib—EPHA2—liver—bile duct cancer	0.000508	0.00519	CbGeAlD
Crizotinib—ABL2—lymph node—bile duct cancer	0.000497	0.00508	CbGeAlD
Crizotinib—MAP3K3—liver—bile duct cancer	0.000496	0.00507	CbGeAlD
Crizotinib—MAP4K5—liver—bile duct cancer	0.000496	0.00507	CbGeAlD
Crizotinib—TEK—liver—bile duct cancer	0.000496	0.00507	CbGeAlD
Crizotinib—ABL1—pancreas—bile duct cancer	0.000491	0.00502	CbGeAlD
Crizotinib—BMP2K—lymph node—bile duct cancer	0.000491	0.00502	CbGeAlD
Crizotinib—PTK2B—lymph node—bile duct cancer	0.000474	0.00484	CbGeAlD
Crizotinib—RIPK2—lymph node—bile duct cancer	0.00047	0.0048	CbGeAlD
Crizotinib—YES1—liver—bile duct cancer	0.000458	0.00468	CbGeAlD
Crizotinib—EPHA4—lymph node—bile duct cancer	0.000454	0.00464	CbGeAlD
Crizotinib—STK10—liver—bile duct cancer	0.000454	0.00464	CbGeAlD
Crizotinib—TAOK3—liver—bile duct cancer	0.000452	0.00462	CbGeAlD
Crizotinib—MAP3K2—lymph node—bile duct cancer	0.000445	0.00455	CbGeAlD
Crizotinib—SRC—liver—bile duct cancer	0.00044	0.0045	CbGeAlD
Crizotinib—PTK2—lymph node—bile duct cancer	0.000436	0.00446	CbGeAlD
Crizotinib—TBK1—lymph node—bile duct cancer	0.000436	0.00446	CbGeAlD
Crizotinib—TYK2—lymph node—bile duct cancer	0.000433	0.00443	CbGeAlD
Crizotinib—IRAK1—lymph node—bile duct cancer	0.000428	0.00437	CbGeAlD
Crizotinib—RPS6KB1—lymph node—bile duct cancer	0.00042	0.00429	CbGeAlD
Crizotinib—LCK—lymph node—bile duct cancer	0.000417	0.00426	CbGeAlD
Crizotinib—FGR—lymph node—bile duct cancer	0.000417	0.00426	CbGeAlD
Crizotinib—AXL—lymph node—bile duct cancer	0.000415	0.00425	CbGeAlD
Crizotinib—SLK—lymph node—bile duct cancer	0.0004	0.00409	CbGeAlD
Crizotinib—EPHB4—lymph node—bile duct cancer	0.000397	0.00406	CbGeAlD
Crizotinib—CSF1R—liver—bile duct cancer	0.000395	0.00404	CbGeAlD
Crizotinib—JAK2—lymph node—bile duct cancer	0.000394	0.00403	CbGeAlD
Crizotinib—EPHA2—lymph node—bile duct cancer	0.000389	0.00398	CbGeAlD
Crizotinib—TEK—lymph node—bile duct cancer	0.00038	0.00388	CbGeAlD
Crizotinib—MAP3K3—lymph node—bile duct cancer	0.00038	0.00388	CbGeAlD
Crizotinib—MAP4K5—lymph node—bile duct cancer	0.00038	0.00388	CbGeAlD
Crizotinib—EPHB6—lymph node—bile duct cancer	0.000363	0.00371	CbGeAlD
Crizotinib—YES1—lymph node—bile duct cancer	0.000351	0.00359	CbGeAlD
Crizotinib—STK10—lymph node—bile duct cancer	0.000348	0.00356	CbGeAlD
Crizotinib—TAOK3—lymph node—bile duct cancer	0.000346	0.00354	CbGeAlD
Crizotinib—SRC—lymph node—bile duct cancer	0.000338	0.00345	CbGeAlD
Crizotinib—ABL1—liver—bile duct cancer	0.000312	0.00319	CbGeAlD
Crizotinib—CSF1R—lymph node—bile duct cancer	0.000303	0.0031	CbGeAlD
Crizotinib—CYP3A5—pancreas—bile duct cancer	0.000287	0.00294	CbGeAlD
Crizotinib—ABL1—lymph node—bile duct cancer	0.00024	0.00245	CbGeAlD
Crizotinib—CYP3A5—liver—bile duct cancer	0.000183	0.00187	CbGeAlD
Crizotinib—ABCB1—pancreas—bile duct cancer	0.000153	0.00156	CbGeAlD
Crizotinib—CYP3A4—liver—bile duct cancer	0.000137	0.0014	CbGeAlD
Crizotinib—ABCB1—liver—bile duct cancer	9.72e-05	0.000993	CbGeAlD
Crizotinib—ABCB1—lymph node—bile duct cancer	7.45e-05	0.000762	CbGeAlD
Crizotinib—LYN—Innate Immune System—HRAS—bile duct cancer	5.43e-06	2.68e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—bile duct cancer	5.4e-06	2.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—bile duct cancer	5.4e-06	2.66e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—bile duct cancer	5.38e-06	2.66e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—bile duct cancer	5.38e-06	2.65e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—bile duct cancer	5.38e-06	2.65e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SMAD4—bile duct cancer	5.38e-06	2.65e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—bile duct cancer	5.35e-06	2.64e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—bile duct cancer	5.33e-06	2.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—bile duct cancer	5.32e-06	2.63e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—bile duct cancer	5.32e-06	2.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—bile duct cancer	5.31e-06	2.62e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—bile duct cancer	5.3e-06	2.62e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—bile duct cancer	5.28e-06	2.61e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—bile duct cancer	5.27e-06	2.6e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—bile duct cancer	5.26e-06	2.6e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—bile duct cancer	5.25e-06	2.59e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KRAS—bile duct cancer	5.24e-06	2.59e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—bile duct cancer	5.24e-06	2.59e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KRAS—bile duct cancer	5.23e-06	2.58e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—bile duct cancer	5.21e-06	2.57e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—bile duct cancer	5.19e-06	2.56e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—bile duct cancer	5.17e-06	2.55e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—bile duct cancer	5.17e-06	2.55e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—bile duct cancer	5.17e-06	2.55e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—bile duct cancer	5.17e-06	2.55e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—bile duct cancer	5.15e-06	2.54e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—bile duct cancer	5.15e-06	2.54e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—KRAS—bile duct cancer	5.15e-06	2.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—bile duct cancer	5.08e-06	2.51e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—bile duct cancer	5.07e-06	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—bile duct cancer	5.06e-06	2.5e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KRAS—bile duct cancer	5.06e-06	2.5e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—bile duct cancer	5.05e-06	2.49e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—bile duct cancer	5.04e-06	2.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFBR2—bile duct cancer	5.03e-06	2.48e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—bile duct cancer	5.03e-06	2.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—KRAS—bile duct cancer	5.02e-06	2.48e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KRAS—bile duct cancer	5.02e-06	2.48e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—bile duct cancer	5.01e-06	2.47e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—bile duct cancer	4.99e-06	2.46e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—bile duct cancer	4.99e-06	2.46e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—bile duct cancer	4.99e-06	2.46e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—bile duct cancer	4.95e-06	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—bile duct cancer	4.94e-06	2.44e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—bile duct cancer	4.92e-06	2.43e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—bile duct cancer	4.92e-06	2.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—bile duct cancer	4.91e-06	2.42e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—bile duct cancer	4.9e-06	2.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—bile duct cancer	4.86e-06	2.4e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—bile duct cancer	4.86e-06	2.4e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GNAS—bile duct cancer	4.85e-06	2.39e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—bile duct cancer	4.84e-06	2.39e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—bile duct cancer	4.8e-06	2.37e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IDH2—bile duct cancer	4.8e-06	2.37e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—bile duct cancer	4.77e-06	2.35e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SMAD4—bile duct cancer	4.76e-06	2.35e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—bile duct cancer	4.73e-06	2.33e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—bile duct cancer	4.71e-06	2.32e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—bile duct cancer	4.67e-06	2.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—bile duct cancer	4.67e-06	2.3e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—bile duct cancer	4.65e-06	2.3e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—bile duct cancer	4.63e-06	2.29e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—bile duct cancer	4.59e-06	2.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—bile duct cancer	4.58e-06	2.26e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—bile duct cancer	4.57e-06	2.26e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—bile duct cancer	4.57e-06	2.25e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GNAS—bile duct cancer	4.55e-06	2.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—bile duct cancer	4.53e-06	2.24e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—bile duct cancer	4.5e-06	2.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—bile duct cancer	4.49e-06	2.21e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—bile duct cancer	4.46e-06	2.2e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—bile duct cancer	4.45e-06	2.2e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—bile duct cancer	4.45e-06	2.2e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—bile duct cancer	4.43e-06	2.19e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—bile duct cancer	4.43e-06	2.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—bile duct cancer	4.42e-06	2.18e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC5A5—bile duct cancer	4.42e-06	2.18e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—bile duct cancer	4.41e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—bile duct cancer	4.37e-06	2.16e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—bile duct cancer	4.35e-06	2.15e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—bile duct cancer	4.32e-06	2.13e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—bile duct cancer	4.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—bile duct cancer	4.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—bile duct cancer	4.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—bile duct cancer	4.28e-06	2.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—bile duct cancer	4.27e-06	2.11e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—bile duct cancer	4.27e-06	2.11e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—bile duct cancer	4.27e-06	2.11e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—bile duct cancer	4.26e-06	2.1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—bile duct cancer	4.24e-06	2.09e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—bile duct cancer	4.24e-06	2.09e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—bile duct cancer	4.24e-06	2.09e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—bile duct cancer	4.22e-06	2.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—bile duct cancer	4.2e-06	2.07e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—bile duct cancer	4.17e-06	2.06e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—bile duct cancer	4.16e-06	2.05e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—bile duct cancer	4.15e-06	2.05e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IDH1—bile duct cancer	4.12e-06	2.04e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—bile duct cancer	4.12e-06	2.03e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—bile duct cancer	4.11e-06	2.03e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—bile duct cancer	4.11e-06	2.03e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—bile duct cancer	4.11e-06	2.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—bile duct cancer	4.09e-06	2.02e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—bile duct cancer	4.06e-06	2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—bile duct cancer	4.04e-06	2e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—bile duct cancer	4.03e-06	1.99e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—bile duct cancer	4.03e-06	1.99e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—bile duct cancer	4.02e-06	1.98e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—bile duct cancer	4.01e-06	1.98e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—bile duct cancer	3.97e-06	1.96e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—bile duct cancer	3.94e-06	1.94e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—bile duct cancer	3.94e-06	1.94e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—bile duct cancer	3.93e-06	1.94e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—bile duct cancer	3.92e-06	1.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—bile duct cancer	3.9e-06	1.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—bile duct cancer	3.89e-06	1.92e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—bile duct cancer	3.85e-06	1.9e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—bile duct cancer	3.81e-06	1.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—bile duct cancer	3.81e-06	1.88e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—bile duct cancer	3.8e-06	1.88e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—bile duct cancer	3.8e-06	1.88e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—bile duct cancer	3.8e-06	1.87e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—bile duct cancer	3.78e-06	1.87e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—bile duct cancer	3.77e-06	1.86e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—bile duct cancer	3.75e-06	1.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—bile duct cancer	3.74e-06	1.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—bile duct cancer	3.73e-06	1.84e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—bile duct cancer	3.72e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—bile duct cancer	3.72e-06	1.84e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—bile duct cancer	3.7e-06	1.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—bile duct cancer	3.7e-06	1.83e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—bile duct cancer	3.68e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—bile duct cancer	3.67e-06	1.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—bile duct cancer	3.65e-06	1.8e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—bile duct cancer	3.6e-06	1.78e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—bile duct cancer	3.55e-06	1.75e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—bile duct cancer	3.54e-06	1.75e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—bile duct cancer	3.54e-06	1.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—bile duct cancer	3.53e-06	1.74e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—bile duct cancer	3.49e-06	1.72e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—bile duct cancer	3.49e-06	1.72e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—bile duct cancer	3.48e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—bile duct cancer	3.48e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—bile duct cancer	3.47e-06	1.71e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—bile duct cancer	3.46e-06	1.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—bile duct cancer	3.45e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—bile duct cancer	3.45e-06	1.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—bile duct cancer	3.44e-06	1.7e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAS—bile duct cancer	3.43e-06	1.69e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—bile duct cancer	3.41e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—bile duct cancer	3.4e-06	1.68e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—bile duct cancer	3.39e-06	1.67e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—bile duct cancer	3.39e-06	1.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—bile duct cancer	3.34e-06	1.65e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—bile duct cancer	3.34e-06	1.65e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—bile duct cancer	3.3e-06	1.63e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—bile duct cancer	3.27e-06	1.61e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—bile duct cancer	3.27e-06	1.61e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—bile duct cancer	3.24e-06	1.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—bile duct cancer	3.24e-06	1.6e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—bile duct cancer	3.24e-06	1.6e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—bile duct cancer	3.23e-06	1.59e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—bile duct cancer	3.22e-06	1.59e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—bile duct cancer	3.21e-06	1.59e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—bile duct cancer	3.2e-06	1.58e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—bile duct cancer	3.2e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—bile duct cancer	3.16e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—bile duct cancer	3.15e-06	1.55e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—bile duct cancer	3.15e-06	1.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—bile duct cancer	3.14e-06	1.55e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—bile duct cancer	3.13e-06	1.55e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—bile duct cancer	3.1e-06	1.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—bile duct cancer	3.1e-06	1.53e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—bile duct cancer	3.06e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—bile duct cancer	3.05e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—bile duct cancer	3.04e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—bile duct cancer	3.02e-06	1.49e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—bile duct cancer	3.01e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—bile duct cancer	3.01e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—bile duct cancer	2.98e-06	1.47e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—bile duct cancer	2.97e-06	1.47e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—bile duct cancer	2.96e-06	1.46e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—bile duct cancer	2.95e-06	1.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—bile duct cancer	2.91e-06	1.43e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—bile duct cancer	2.89e-06	1.43e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—bile duct cancer	2.87e-06	1.41e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—bile duct cancer	2.86e-06	1.41e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—bile duct cancer	2.83e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—bile duct cancer	2.81e-06	1.39e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—bile duct cancer	2.79e-06	1.38e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—bile duct cancer	2.78e-06	1.37e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—bile duct cancer	2.74e-06	1.35e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—bile duct cancer	2.73e-06	1.35e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	2.72e-06	1.34e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—bile duct cancer	2.72e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—bile duct cancer	2.7e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—bile duct cancer	2.69e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—bile duct cancer	2.66e-06	1.31e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—bile duct cancer	2.66e-06	1.31e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—bile duct cancer	2.64e-06	1.3e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—bile duct cancer	2.64e-06	1.3e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—bile duct cancer	2.62e-06	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—bile duct cancer	2.61e-06	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—bile duct cancer	2.61e-06	1.29e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—bile duct cancer	2.6e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—bile duct cancer	2.6e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—bile duct cancer	2.59e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—bile duct cancer	2.58e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—bile duct cancer	2.54e-06	1.26e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—bile duct cancer	2.52e-06	1.25e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—bile duct cancer	2.49e-06	1.23e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—bile duct cancer	2.49e-06	1.23e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—bile duct cancer	2.48e-06	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—bile duct cancer	2.44e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—bile duct cancer	2.43e-06	1.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—bile duct cancer	2.41e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—bile duct cancer	2.4e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—bile duct cancer	2.39e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—bile duct cancer	2.38e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—bile duct cancer	2.29e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—bile duct cancer	2.29e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—bile duct cancer	2.29e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—bile duct cancer	2.28e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—bile duct cancer	2.25e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—bile duct cancer	2.19e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—bile duct cancer	2.14e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—bile duct cancer	2.13e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—bile duct cancer	2.12e-06	1.05e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAS—bile duct cancer	2.11e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—bile duct cancer	2.09e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—bile duct cancer	2.04e-06	1.01e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—bile duct cancer	2.03e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—bile duct cancer	2.03e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—bile duct cancer	2e-06	9.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—bile duct cancer	1.97e-06	9.73e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—bile duct cancer	1.96e-06	9.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—bile duct cancer	1.91e-06	9.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—bile duct cancer	1.88e-06	9.3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—bile duct cancer	1.85e-06	9.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—bile duct cancer	1.84e-06	9.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—bile duct cancer	1.83e-06	9.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—bile duct cancer	1.75e-06	8.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—bile duct cancer	1.74e-06	8.61e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—bile duct cancer	1.67e-06	8.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—bile duct cancer	1.6e-06	7.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—bile duct cancer	1.55e-06	7.65e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—bile duct cancer	1.48e-06	7.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—bile duct cancer	1.42e-06	7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.14e-06	5.6e-06	CbGpPWpGaD
